Doudna research team finds CRISPR-Csm delivery potentially outperforms RNAi, Cas13
While RNAi and Cas13 have been used as some of the early methods for gene silencing, a new preprint from top researchers says there might be something better coming down the pike.
A group of UC Berkeley researchers, comprising famed biochemist and Nobel Prize winner Jennifer Doudna and her lab members David Colognori and Marena Trinidad, has described a new method that can provide potentially safer and more efficient gene editing: CRISPR-Csm.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 154,000+ biopharma pros reading Endpoints daily — and it's free.